Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX)
83.49
+0.00 (0.00%)
NASDAQ· Last Trade: Jul 9th, 6:12 AM EDT
Detailed Quote
Previous Close
83.49
Open
-
Bid
83.45
Ask
83.75
Day's Range
N/A - N/A
52 Week Range
25.83 - 83.63
Volume
92
Market Cap
4.51B
PE Ratio (TTM)
-16.90
EPS (TTM)
-4.9
Dividend & Yield
N/A (N/A)
1 Month Average Volume
6,147,153
Chart
About Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX)
Crinetics Pharmaceuticals Inc is a biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases and disorders. The company leverages its expertise in the field of endocrine science to discover and create targeted treatments that address unmet medical needs. Crinetics aims to provide effective solutions for patients suffering from conditions related to hormonal imbalances by advancing its pipeline of novel compounds through various stages of clinical development. Through its commitment to research and development, the company strives to enhance the quality of life for individuals affected by complex endocrine issues. Read More
Crinetics Pharmaceuticals (NASDAQ:CRNX) has outperformed the market over the past 5 years by 21.74% on an annualized basis producing an average annual return of 33.07%. Currently, Crinetics Pharmaceuticals has a market
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Crinetics Pharmaceuticals, Inc. (NasdaqGS: CRNX) to Vertex Pharmaceuticals Incorporated (NasdaqGS: VRTX). Under the terms of the proposed transaction, shareholders of Crinetics will receive $85.00 in cash for each share of Crinetics that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for $10 billion at $85 per share, adding the approved drug PALSONIFY and pipeline candidate Atumelant to expand beyond its cystic fibrosis franchise.
Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) shares moved upwards by 98.7% to $83.53 during Tuesday's regular session. The company's market cap stands at $4.4 billion. Tvardi Therapeutics (NASDAQ:TVRD)
Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) stock increased by 98.9% to $83.59 during Tuesday's pre-market session. The market value of their outstanding shares is at $4.4 billion. Bluejay Diagnostics
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) to Vertex Pharmaceuticals Incorporated for $85.00 per share in cash.
Gainers Vicore Pharma Holding (NASDAQ:VCRE) stock rose 149.8% to $42.47 during Monday's after-market session. Crinetics Pharmaceuticals (NASDAQ:CRNX) stock moved upwards by 99.85% to $84.0. The company's
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, for a total equity value of approximately $10.0 billion, or approximately $8.8 billion net of estimated cash acquired. The transaction was unanimously approved by both the Vertex and Crinetics Boards of Directors and is anticipated to close in the third quarter of 2026.
SAN DIEGO, June 30, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.
Data show investigational atumelnant drove sustained androgen reductions while enabling lowering of glucocorticoid supplementation to physiologically normal levels in adults with classic CAH
Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms
Everyday Advocacy provides people living with endocrine and endocrine-related conditions with education, support, and tools to facilitate more impactful healthcare team interactions
Oral presentation features open label extension PALSONIFY™ (paltusotine) data, reinforcing its best-in-class potential in acromegaly following recent U.S. and E.U. approvals
SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the Jefferies Global Healthcare Conference, taking place June 2-4, 2026 in New York, NY.
